Date Filed | Type | Description |
10/04/2023 |
SC 13D
| Sire Group Ltd. reports a 16.7% stake in Titan Pharmaceuticals, Inc. |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/20/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
06/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
05/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
05/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
02/09/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits Interactive ... |
01/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
12/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/15/2022 |
8-K
| Quarterly results |
12/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
09/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/17/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/16/2022 |
8-K
| Quarterly results |
08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/05/2022 |
8-K
| Quarterly results |
07/25/2022 |
DEFN14A
| Form DEFN14A - Definitive proxy statement filed by non-management: |
07/22/2022 |
8-K
| Quarterly results |
07/22/2022 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
07/14/2022 |
PREN14A
| Form PREN14A - Non-management preliminary proxy statements: |
07/13/2022 |
8-K
| Quarterly results |
07/11/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
07/11/2022 |
8-K
| Quarterly results |
07/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/05/2022 |
8-K
| Quarterly results |
06/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/02/2022 |
8-K
| Quarterly results |
|